API | cinaciguat

cinaciguat Report issue

Small molecule Experimental

AACT MeSH PubChem

Active Ingredient History

NOW

Cinaciguat is an experimental drug for the treatment of acute decompensated heart failure. ^Wikipedia

Chemistry

SMILES: O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1
InChIKey: WPYWMXNXEZFMAK-UHFFFAOYSA-N
Mol. Mass: 565.71
ALogP: 7.05 Partition coefficient
ChEMBL Molecule:
cinaciguat

More Chemistry

Pharmacology

Mechanisms of Action:
- Guanylate cyclase soluble subunit alpha-1 (Homo sapiens) ^UniProt
- Guanylate cyclase soluble subunit beta-1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

4-((4-carboxybutyl)(2-((4-phenethylbenzol) oxy)phenethyl)amino)methyl(benzoic) acid | bay582667 | bay 58-2667 | cinaciguat

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Heart Failure (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue